Immix Biopharma on Track to Dose NXC-201 Patients in United States
April 18, 2024 09:32 ET
|
Immix Biopharma, Inc.
Scheduling U.S. site initiation visits April and May 2024On track to dose relapsed/refractory AL Amyloidosis patients with CAR-T NXC-201 at New York City lead site and other leading U.S....
Immix Biopharma Announces Major Comprehensive Cancer Center as Lead Site for NXC-201 AL Amyloidosis Clinical Trial
March 20, 2024 09:46 ET
|
Immix Biopharma, Inc.
LOS ANGELES, CA, March 20, 2024 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (Nasdaq: IMMX) (“ImmixBio”, “Company”, “We” or “Us” or “IMMX”), a clinical-stage biopharmaceutical company trailblazing cell...
Immix Biopharma Announces “Be Proactive in AL” AL Amyloidosis Awareness Initiative
March 05, 2024 09:35 ET
|
Immix Biopharma, Inc.
LOS ANGELES, CA, March 05, 2024 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (Nasdaq: IMMX) (“ImmixBio”, “Company”, “We” or “Us” or “IMMX”), a clinical-stage biopharmaceutical company trailblazing cell...
Immix Biopharma 12 Month Review Progress Update
February 21, 2024 09:31 ET
|
Immix Biopharma, Inc.
LOS ANGELES, Feb. 21, 2024 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (Nasdaq: IMMX), a clinical-stage biopharmaceutical company trailblazing cell therapies in autoimmune disease, today announced its...
Immix Biopharma Announces Closing of $15 Million Public Offering of Common Stock
February 08, 2024 16:45 ET
|
Immix Biopharma, Inc.
LOS ANGELES, CA, Feb. 08, 2024 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“ImmixBio”, “Company”, “We” or “Us” or “IMMX”), a clinical-stage biopharmaceutical company pioneering personalized therapies...
Immix Biopharma Awarded European Union Orphan Drug Designation for NXC-201 in AL Amyloidosis
February 07, 2024 09:37 ET
|
Immix Biopharma, Inc.
European Orphan Drug Designation (“ODD”) qualifies NXC-201 for: 10 years of market exclusivity once authorized in the EUAccess to the EU centralized authorization procedureReduced fees for EU...
Immix Biopharma Announces Pricing of $15 Million Public Offering of Common Stock
February 05, 2024 22:30 ET
|
Immix Biopharma, Inc.
LOS ANGELES, CA, Feb. 05, 2024 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“ImmixBio”, “Company”, “We” or “Us” or “IMMX”), a clinical-stage biopharmaceutical company pioneering personalized therapies...
Immix Biopharma Announces Proposed Public Offering of Common Stock
February 05, 2024 15:20 ET
|
Immix Biopharma, Inc.
LOS ANGELES, Feb. 05, 2024 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (Nasdaq: IMMX) (the “Company”), a clinical-stage biopharmaceutical company trailblazing cell therapies in autoimmune disease,...
Immix Biopharma Statement On January 2024 FDA Labeling Change Notification For Approved CAR-T Products
January 24, 2024 08:35 ET
|
Immix Biopharma, Inc.
LOS ANGELES, CA, Jan. 24, 2024 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“Immix Biopharma”, “Company”, “We” or “Us”, Nasdaq:IMMX), a clinical-stage biopharmaceutical company trailblazing cell...
Immix Biopharma Announces Dr. Vaishali Sanchorawala, AL Amyloidosis Thought Leader, Director of the Amyloidosis Center at Boston University and Boston Medical Center, Joins Scientific Advisory Board
January 04, 2024 09:34 ET
|
Immix Biopharma, Inc.
LOS ANGELES, Jan. 04, 2024 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“Immix Biopharma”, “Company”, “We” or “Us”, Nasdaq:IMMX), announced that effective today, Vaishali Sanchorawala, MD, has joined...